SGM-101

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameSGM-101
Drug Alias NameSGM-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsDiagnostic agent (In vivo) +[4] 
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsDiagnostic imaging enhancers
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsBrain metastasesBrain DiseasesColonic Diseases +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsItaly +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSurgimab Sas
China Registration ClassN/A

Develop Information

Active CompaniesSurgimab SasLeiden University Medical Center
Inactive CompaniesN/A
Active IndicationsBrain metastasesBrain DiseasesColonic Diseases +[10] 
Inactive IndicationsPancreatic NeoplasmsRectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A